Status:
COMPLETED
Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia
Lead Sponsor:
University of Illinois at Chicago
Collaborating Sponsors:
Janssen, LP
Weill Medical College of Cornell University
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE3
Brief Summary
The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from skills training. The ...
Detailed Description
The study will be conducted at the University of Illinois at Chicago and New York Presbyterian Hospital-Westchester Division. Patients with schizophrenia or schizoaffective disorder who are considered...
Eligibility Criteria
Inclusion
- Schizophrenia or schizoaffective disorder
- Ages 18-55
- Ability to give informed consent
- Good general physical health or stable chronic medical conditions
- Ability to be on a single antipsychotic medication
- History of inattentiveness in psychosocial treatment settings
- Poor social skills
- Must be receiving a single antipsychotic medication
- Must be clinically stable - defined by the absence of prominent delusions, hallucinations, disorganized speech, or grossly disorganized or catatonic behavior. However, there must also be continuing evidence of impairment, as indicated by the presence of negative symptoms or two or more symptoms of schizophrenia listed in Criterion A of the DSM-IV, in attenuated form (e.g., odd beliefs, unusual perceptual experiences).
Exclusion
- Inability to give informed consent
- Substance dependency in the past 6 months
- Diagnosis of dementia
- Significant head injury or other brain injury leading to cognitive impairment
- Mental retardation (premorbid IQ \< 65)
- Pregnant or nursing
- Allergy or other significant adverse reaction to risperidone
- Contraindication to Risperdal Consta as only antipsychotic
- Currently taking risperidone
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00148083
Start Date
September 1 2005
End Date
March 1 2006
Last Update
May 15 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
2
New York Presbyterian Hospital
White Plains, New York, United States, 10605